-The Times of India SURAT: For 18 years, he took orders from people for piping hot bhajiyas that his father prepared on a small handcart outside Chikhli bus stop in Navsari. Now, he is all set to deliver orders. Subhash Tripathi is awaiting his appointment as a civil judge. After practicing as a lawyer for five years in Chikhli court, Tripathi cleared the exam for judges recently. The family migrated from Varanasi...

-The Telegraph The sudden arrest of Amway India's top brass on Monday has focused the spotlight on the crumbling fault lines and the grey areas in the demarcation between some of the world's best-known direct selling companies and the dodgy Ponzi schemes that promise huge returns to gullible investors and have lately grabbed all the sensational headlines in Bengal. William S. Pinckney, managing director of Amway India, and two directors of the...

-The Hindu     The killings of Mahendra Karma and his colleagues call not for retributive violence but for a deeper reflection on the discontent among the tribals of central India and their dispossession In the summer of 2006, I had a long conversation with Mahendra Karma, the Chhattisgarh Congress leader who was killed in a terror attack by the Naxalites last week. I was not alone - with me were five other members...

-The Economic Times NEW DELHI: You may end up saving more in the months ahead with the Employees Provident Fund Organization (EPFO) readying to re-notify a new definition of "compensation" that will include all your allowances, amid intense lobbying against the move by industry bodies. Currently, employers get away by contributing only 12% of the basic salary and dearness allowance, which is not paid by most companies, towards their share of "matching"...

-The Hindu   Ranbaxy's fraudulent practices may have jeopardised millions of lives in India, Africa and the U.S. Exactly two weeks ago, the pharmaceuticals industry was rocked by revelations that one of the world's largest generic drug manufacturers, Ranbaxy Laboratories, pleaded guilty to seven federal criminal charges stemming from its fraudulent production practices dating back to 2008, and agreed to pay U.S. regulators $500 million in fines. Much has since been said about Ranbaxy's...